Diabetes drug trial halted: could BMF-219 have boosted insulin?

NCT ID NCT06152042

Terminated Disease control Sponsor: Biomea Fusion Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called BMF-219 in people with type 1 diabetes to see if it could help their bodies produce more insulin. The trial was stopped early, but researchers planned to compare insulin levels between those who got the drug and those who got a placebo. About 37 adults with type 1 diabetes were enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC.

Norman, Oklahoma, 73069, United States
Centricity Research

Toronto, Ontario, Canada
Consano Clinical Research, LLC

Shavano Park, Texas, 78231, United States
Diabetes & Glandular Disease Clinic, P.A.

San Antonio, Texas, 78229, United States
Dr. T.G Elliott Inc. dba BC Diabetes

Vancouver, British Columbia, Canada
Lucas Research, Inc.

Morehead City, North Carolina, 28577, United States
Manassas Clinical Research Center

Manassas, Virginia, 20110, United States
Oceanic Research Group

North Miami Beach, Florida, 33169, United States
Texas Diabetes & Endocrinology

Round Rock, Texas, 78681, United States
University Diabetes & Endocrine Consultants

Chattanooga, Tennessee, 37411, United States
Velocity Clinical Research

Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.